I

Immunome, Inc. Tech Stack

Clinical-stage oncology company advancing targeted therapies and ADCs

Biotechnology Research Bothell, Washington 51–200 employees Public Company

Immunome is a public clinical-stage oncology company developing targeted cancer therapies, including gamma secretase inhibitors, antibody-drug conjugates (ADCs), and radioligands. The tech stack reveals a regulatory and manufacturing-heavy operation: Veeva CDMS, Medidata Rave, SAS, and NONMEM dominate, paired with analytical chemistry tools (LC-MS/MS, MATLAB). Hiring is senior-skewed (29 senior roles, 15 directors) and concentrated in research, healthcare, and manufacturing—consistent with Phase 3 and Phase 1 trial execution and the imminent commercial launch of varegacestat.

Tech Stack 12 technologies

Core StackSAS MATLAB NetSuite Medidata Rave Veeva CDMS R NONMEM Shiny LC-MS LC-MS/MS Cornerstone CDISC

What Immunome, Inc. Is Building

◆Challenges

Timely regulatory submissions
Ensuring regulatory compliance worldwide
Enhancing statistical programming infrastructure
Vendor management for biomarker assays
Regulatory inspection readiness
Technology transfer to cdmo
Advancing oncology programs through pivotal trials
Regulatory compliance across modalities
Advancing pipeline of targeted cancer therapies
Launching first commercial therapy

▲Active Projects

Launch of varegacestat
Clinical study statistical programming
Field market access strategy
Adc analytical method development
Development of drug safety databases
Preparation of safety reports
Clinical trial protocols for oncology drug candidates
Global regulatory cmc strategy development
Regulatory submission strategy
Document template development

Hiring Activity

Accelerating55 roles · 25 in 30d

Department

Research

11

Healthcare

8

Manufacturing

7

Data

6

Legal

4

Ops

4

Finance

3

Product

2

Seniority

Senior

29

Director

15

Principal

6

Manager

2

VP

2

Notable leadership hires: Global Regulatory Lead, CMC Technical Lead, Market Access Director

Company intelligence

Find more companies like Immunome, Inc. by tech stack, pain points and active projects

Get started free

About Immunome, Inc.

Immunome develops first-in-class and best-in-class targeted oncology therapies. The pipeline spans three lead programs: varegacestat (gamma secretase inhibitor in Phase 3 for desmoid tumors), IM-1021 (ROR1-targeted ADC in Phase 1), and IM-3050 (FAP-targeted radioligand post-IND clearance), plus preclinical ADC candidates. The company is headquartered in Bothell, Washington, and operates as a public company with 51–200 employees. Active projects center on clinical trial execution, regulatory strategy, drug safety infrastructure, and preparation for the first commercial launch—reflecting transition from development into early-stage commercialization.

HeadquartersBothell, Washington

Company Size51–200 employees

Hiring MarketsUnited States

Frequently Asked Questions

What is Immunome's lead drug candidate?

Varegacestat (formerly AL102), a gamma secretase inhibitor currently in Phase 3 trials for desmoid tumors. It is the most advanced program and subject of ongoing launch preparation efforts.

What tech does Immunome use for clinical trials?

Medidata Rave and Veeva CDMS for clinical data management; SAS, R, and NONMEM for statistical programming and pharmacokinetic modeling; LC-MS/MS for analytical chemistry.